Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP2 With Tivozanib in Metastatic Renal Cell Carcinoma
NCT07218692Phase 2Withdrawn
- Sponsor
- City of Hope
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Antibody Conjugates, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of sturlimogene erparepvec in renal cell carcinoma (RCC), sponsored by City of Hope. Planned start Aug 2026; status: withdrawn.
02
Drugs
sturlimogene erparepvec
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07218692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07218692.